Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation
Full article: https://jamanetwork.com/journals/jamaoncology/article-abstract/2678466
Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this study, researchers showed that among women with
BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)
Questions To Ask Your Health Care Provider
- Should I consider using HT after risk-reducing ovary removal? After menopause?
- What kind of HT would be most appropriate for me?
- What are other options for managing menopause without HT?
- What risks are associated with taking or not taking HT after removal of my ovaries?
- Can you refer me to a menopause expert?
Open Clinical Trials
The following are studies on menopause and menopause management for survivors and previvors:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.